This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

The majority (over 9.4 million shares) will go to the Gates Foundation. An additional 943,384 shares are being donated to the ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Gui Santos and Quinten Post each played a role for the Golden State Warriors during the 2024-25 season. On Sunday, Anthony ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from all over the ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...